Regional and systemic serum concentrations of 5-fluorouracil after portal and intravenous infusion: An experimental study in dogs
Tóm tắt
The serum and urinary concentrations of 5-FU after continuous portal and jugular infusion have been followed by means of a highly sensitive microbiological assay method. Our data indicate that more than 90% of 5-FU was eliminated in the liver after continuous portal infusion of 0.625 mg × kg
−1
× hr
−1
,corresponding to a dose of 15 mg × kg
−1
×24 hr
−1
.Negligible amounts of intact 5-FU were excreted into the bile, and the urinary excretion was only a few percent of the amount infused. The arterial concentration was on average tenfold higher during the continuous jugular infusion than after the continuous portal infusion, indicating that the route of administration has a pronounced effect on the disposition of 5-FU. Twenty-three percent of the jugular dose reached the liver; 77% was degraded by extrahepatic metabolism. Of these, degradation in the prehepatic splanchnic area accounted for 15%.
Tài liệu tham khảo
F. J. Ansfield. A less toxic fluorouracil dosage schedule.JAMA 190:686–698 (1964).
H. W. Brucker and W. A. Creasy. The administration of 5-fluorouracil by mouth.Cancer 33:14–18 (1974).
J. Dillaha, G. T. Jansen, W. M. Honeycutt, and G. A. Hold. Further studies with topical 5-fluorouracil.Arch. Determato. 92:410–417 (1965).
C. E. Myers, R. Diasio, A. M. Eliot, and B. O. Chabner. Pharmacokinetics of the fluoropyrimidines: Implication for their clinical use.Cancer Treat. Rev. 3:175–183 (1976).
F. Ansfield, J. Klotz, T. Nealon, G. Ramirez, J. Minton, G. Hill, W. Wilson, H. Davis, and G. Cornell. A phase III study comparing the clinical utility of four regimens of 5-fluorourocil: A preliminary report.Cancer 39:34–40 (1977).
O. Almersjö, B. Gustavsson, and L. O. Hafström. Results of regional portal infusion of 5-fluorouracil to patients with primary and secondary liver cancer.Ann. Chir. Gynaecol. Fenn. 65:27–32 (1976).
O. Almersjö, A. Brandberg, B. Gustavsson, L. O. Hafström, A. Falsén, and G.-B. Lindblom. Methodological aspects of an agar plate technique for determination of biologically active 5-fluorouracil in blood, urine and bile.Acta Pathol. Microbiol. Scand. 85:227–234 (1977).
O. Almersjö, å. Brandberg, B. Gustavsson, L. O. Hafström and T. Seeman. Inactivation of 5-fluorouracil by the liver during continuous regional and systemic infusion in pigs.Eur. Surg. Res. 8:489–496 (1976).
N. Darle. Xenon133 clearance and liver blood flow.Acta. Chir. Scand. Suppl. 407:5–64 (1970).
H. L. Conn. Equilibrium distribution of radiorenon in tissue: Xenon-hemoglobin association curve.J. Appl. Physiol. 16:1065–1070 (1961).
A. M. Andersen, and J. Ladefoged. Relationship between hematocrit and solubility of133Xe in blood.J. Pharm. Sci. 54:1684–1685 (1965).
N. Darle, R. C. Lim, and F. W. Blaisdell. Effect of glucagon on total liver blood flow in hemorrhagic shock.Acta. Chir. Scand. 140:217–225 (1974).
M. Andreen and L. Irestedt. Decrease of oxygen consumption in the dog liver during temporary arterial occlusion.Acta Physiol. Scand. 98:103–109 (1976).
N. G. Kock, P. Hahnloser, B. Roding, and W. G. Schenk. Interaction between portal and hepatic arterial blood flow: An experimental study in the dog.Surgery 72:414–419 (1977).
C. Finn, and W. Sadee. Determination of 5-fluorouracil (NSC-19 893) plasma levels in rats and man by isotope dilution-mass fragmentography.Cancer Chemother. Rep. (Part I) 59:279–286 (1975).
K. L. Mukherjee and C. Heidelberger. Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.J. Biol. Chem. 235:433–437 (1960).
C. Heidelberger. Fluorinated pyrimidines and their nucleotides. In Sartorelli and Johns (eds.),Antineoplastic and Immunosuppressive Agent, Part II, Springer-Verlag, New York, (1975), pp. 193–231.
P. Fritzon. The catabolism of14C-labeled uracil, dihydrouracil and Β-ureidoproprionic acid in rat liver slices.J. Biol. Chem. 226:223–228 (1957).
D. G. Shand, G. H. Evand, and A. S. Nies. The almost complete hepatic extraction of propanolol during intravenous administration in the dog.Life Sci. 10(1):1417–1421 (1971).
B. Clarkson, A. O'Connor, L. Winston and D. Hutchinson. The physiologic disposition of 5-fluorouracil and 5-fluoro-2′-deoxyuridine in man.Clin. Pharmacol. Ther. 5:581–610 (1964).
W. Sadee and C. G. Wong. Pharmacokinetics of 5-fluorouracil: Interrelationship with biochemical kinetics in monitoring therapy.Clin. Pharmacokin. 2:437–450 (1977).
J. J. Ambre and L. J. Fischer. The effect of prednisolone and other factors on the catabolism of 5-fluorouracil in rats.J. Lab. Clin. Med. 78:343–353 (1971).
M. Chadwick and J. Rogers. The physiological disposition of 5-fluorouracil in mice bearing solid L1210 lymphocytic leukemia.Cancer Res. 32:1045–1056 (1972).
E. R. Garrett, G. H. Hurst, and Russel Green, Jr. Kinetics and mechanisms of drug action on microorganisms. XXIII. Microbial kinetic assay for fluorouracil in biological fluids and its application to human pharmacokinetics.J. Pharm. Sci. 66:1422–1429 (1977).
T. Colton.Statistics in Medicine, 1st ed., Little, Brown, Boston, (1974), p. 219.
B. Gustavsson, A. Brandberg, C. Regårdh, T. Seeman, and O. Almersjö. The concentration of 5-fluorouracil in the systemic circulation and urine during continuous infusion and exclusion of the liver: An experimental study in dogs. Submitted (1979).
O. Almersjö, B. Gustavsson, C. Regårdh, and P. Wåhlén. Pharmacokinetic studies of 5-fluorouracil after oral and intravenous administration in man. Submitted (1979).